Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells.

Medical Oncology
Fei-fei ZhouLiang-ping Xia

Abstract

Elevated activity of the eukaryotic translation initiation factor 4E (eIF4E) plays crucial roles in tumorigenesis and disease progression by disproportionately increasing translation of mRNAs coding proteins that play significant roles in all aspects of malignancy, providing that eIF4E as an attractive target for therapeutic intervention. In this study, we showed that inhibition of eIF4E by small interfering RNAs (siRNA) resulted in cell cycle arrest and suppression of colony formation in MDA-MB-231 triple-negative (TN) breast cancer cells. Migration transwell assay revealed that repression of eIF4E effectively inhibited motility of MDA-MB-231 cancer cells. Importantly, we showed that silencing of eIF4E sensitized MDA-MB-231 cells to chemotherapeutic drugs of cisplatin, adriamycin, paclitaxel and docetaxel as assessed by MTT assay. Moreover, Western blot assay showed that eIF4E siRNA increased Bax/Bcl-2 ratio in MDA-MB-231 cells. Taken together, we showed that knockdown of eIF4E suppressed cell growth and migration, enhanced chemosensitivity, suggesting a potential therapeutic target in TN breast carcinoma.

References

May 30, 1998·Annals of Surgery·B D LiA De Benedetti
Aug 30, 2000·Nature·C M PerouD Botstein
Dec 29, 2000·Cellular and Molecular Life Sciences : CMLS·T V Pestova, C U Hellen
Nov 21, 2002·The Journal of Biological Chemistry·Shunan LiVitaly A Polunovsky
Jan 18, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Kip A WestPhillip A Dennis
Mar 19, 2004·Nature·Hans-Guido WendelScott W Lowe
Apr 20, 2004·Oncogene·Arrigo De Benedetti, Jeremy R Graff
May 28, 2004·Nature Structural & Molecular Biology·Tobias von der HaarJohn E G McCarthy
Dec 17, 2004·Proceedings of the National Academy of Sciences of the United States of America·Alex KentsisKatherine L B Borden
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Dec 13, 2005·Nature Reviews. Drug Discovery·Bryan T HennessyGordon B Mills
Dec 31, 2005·Clinical Breast Cancer·Gabriel N HortobagyiUNKNOWN ABREAST Investigators
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
Apr 25, 2006·Annals of Surgery·Kerry ByrnesBenjamin D Li
Feb 20, 2007·Lancet·Francesco Boccardo, Alessandra Rubagotti
Sep 6, 2007·The Journal of Clinical Investigation·Jeremy R GraffEric G Marcusson
Oct 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lyndsay HarrisUNKNOWN American Society of Clinical Oncology
Feb 5, 2008·Cancer Research·Jeremy R GraffEric G Marcusson
Jul 23, 2008·Molecular Cancer Therapeutics·Alpana SoniFunda Meric-Bernstam
Dec 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bryan P SchneiderLisa A Carey
May 2, 2009·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Junichi Kurebayashi
Jul 31, 2009·Expert Opinion on Pharmacotherapy·Cagatay ArslanKadri Altundag
Jan 6, 2010·Journal of Oncology·Biljana Culjkovic, Katherine L Borden

❮ Previous
Next ❯

Citations

May 21, 2011·BMC Plant Biology·Nuria Sánchez-PonsCarlos M Vicient
Nov 14, 2013·BMC Pharmacology & Toxicology·Zeina NasrJerry Pelletier
Nov 27, 2015·Expert Opinion on Therapeutic Targets·Fouzia GuestiniHironobu Sasano
Jan 19, 2016·Expert Reviews in Molecular Medicine·Chunwan LuYafei Cai
Dec 18, 2015·BBA Clinical·Elma A O'ReillyAmanda McCann
Jul 10, 2014·Expert Opinion on Therapeutic Targets·Filippa PetterssonWilson H Miller
Mar 13, 2014·Chemistry & Biology·Sarah DiabShudong Wang
Jan 3, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Jing-Zhang WangYong Zhang
Sep 26, 2013·The Breast : Official Journal of the European Society of Mastology·Roxana ChioreanIoana Berindan-Neagoe
Sep 8, 2016·Journal of Cancer Research and Clinical Oncology·Xue-Mei JiangJi-Min Zhu
Mar 11, 2017·Current Opinion in Oncology·Vidya P RamamurthyVincent C O Njar
Feb 15, 2018·Cold Spring Harbor Perspectives in Biology·Jennifer Chu, Jerry Pelletier
Aug 26, 2017·Future Medicinal Chemistry·Ella LinehamSimon J Morley
Feb 20, 2018·Experimental and Therapeutic Medicine·Teng PanYadong Wang
May 11, 2019·Journal of Cellular Biochemistry·Asiya BatoolKhurshid I Andrabi
Dec 23, 2016·Cellular and Molecular Life Sciences : CMLS·Jutta SteinbergerJerry Pelletier
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hélène Malka-MahieuStéphan Vagner
Sep 21, 2021·Cellular and Molecular Life Sciences : CMLS·Alice RomagnoliDaniele Di Marino

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.